Loading…

Pharmacological treatment of actinic keratosis

Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment op...

Full description

Saved in:
Bibliographic Details
Published in:Przegląd dermatologiczny 2016-01, Vol.4 (4), p.330-336
Main Authors: Zwierzyńska, Ewa, Zawistowska, Anna, Pietrzak, Bogusława
Format: Article
Language:eng ; pol
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653
cites
container_end_page 336
container_issue 4
container_start_page 330
container_title Przegląd dermatologiczny
container_volume 4
creator Zwierzyńska, Ewa
Zawistowska, Anna
Pietrzak, Bogusława
description Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.
doi_str_mv 10.5114/dr.2016.61784
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636</doaj_id><sourcerecordid>4179545001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</originalsourceid><addsrcrecordid>eNo9kElLA0EQRhtRMEaP3gc8z9j7cpTgEgjoQc9NTS9x4iQduzsH_71ZRCj4oPh4VTyEbgnuBCH83ueOYiI7SZTmZ2hCseat0YadownGjLVUUHmJrkpZYSwNJXSCurdPyGtwaUzLwcHY1BygrsOmNik24OqwGVzzFTLUVIZyjS4ijCXc_OUUfTw9vs9e2sXr83z2sGgdw7i2zAfeS2WcV8QFEaOnQe9HBM_7XnEjJEgswCtMI45ORcFjz7gwkXgjBZui-YnrE6zsNg9ryD82wWCPi5SXFnId3BgsEC6dM6rH1HHiFWgsvANNlQIimdyz7k6sbU7fu1CqXaVd3uzft0QTLZUQiu1b7anlciolh_h_lWB70Gt9tge99qiX_QK5qmxB</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1818675573</pqid></control><display><type>article</type><title>Pharmacological treatment of actinic keratosis</title><source>Publicly Available Content (ProQuest)</source><creator>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</creator><creatorcontrib>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</creatorcontrib><description>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</description><identifier>ISSN: 0033-2526</identifier><identifier>EISSN: 2084-9893</identifier><identifier>DOI: 10.5114/dr.2016.61784</identifier><language>eng ; pol</language><publisher>Poznan: Termedia Publishing House</publisher><subject>actinic keratosis ; clinical studies ; pharmacotherapy</subject><ispartof>Przegląd dermatologiczny, 2016-01, Vol.4 (4), p.330-336</ispartof><rights>Copyright Termedia Publishing House 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1818675573?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25731,27901,27902,36989,44566</link.rule.ids></links><search><creatorcontrib>Zwierzyńska, Ewa</creatorcontrib><creatorcontrib>Zawistowska, Anna</creatorcontrib><creatorcontrib>Pietrzak, Bogusława</creatorcontrib><title>Pharmacological treatment of actinic keratosis</title><title>Przegląd dermatologiczny</title><description>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</description><subject>actinic keratosis</subject><subject>clinical studies</subject><subject>pharmacotherapy</subject><issn>0033-2526</issn><issn>2084-9893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNo9kElLA0EQRhtRMEaP3gc8z9j7cpTgEgjoQc9NTS9x4iQduzsH_71ZRCj4oPh4VTyEbgnuBCH83ueOYiI7SZTmZ2hCseat0YadownGjLVUUHmJrkpZYSwNJXSCurdPyGtwaUzLwcHY1BygrsOmNik24OqwGVzzFTLUVIZyjS4ijCXc_OUUfTw9vs9e2sXr83z2sGgdw7i2zAfeS2WcV8QFEaOnQe9HBM_7XnEjJEgswCtMI45ORcFjz7gwkXgjBZui-YnrE6zsNg9ryD82wWCPi5SXFnId3BgsEC6dM6rH1HHiFWgsvANNlQIimdyz7k6sbU7fu1CqXaVd3uzft0QTLZUQiu1b7anlciolh_h_lWB70Gt9tge99qiX_QK5qmxB</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Zwierzyńska, Ewa</creator><creator>Zawistowska, Anna</creator><creator>Pietrzak, Bogusława</creator><general>Termedia Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>DOA</scope></search><sort><creationdate>20160101</creationdate><title>Pharmacological treatment of actinic keratosis</title><author>Zwierzyńska, Ewa ; Zawistowska, Anna ; Pietrzak, Bogusława</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; pol</language><creationdate>2016</creationdate><topic>actinic keratosis</topic><topic>clinical studies</topic><topic>pharmacotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zwierzyńska, Ewa</creatorcontrib><creatorcontrib>Zawistowska, Anna</creatorcontrib><creatorcontrib>Pietrzak, Bogusława</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Przegląd dermatologiczny</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zwierzyńska, Ewa</au><au>Zawistowska, Anna</au><au>Pietrzak, Bogusława</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological treatment of actinic keratosis</atitle><jtitle>Przegląd dermatologiczny</jtitle><date>2016-01-01</date><risdate>2016</risdate><volume>4</volume><issue>4</issue><spage>330</spage><epage>336</epage><pages>330-336</pages><issn>0033-2526</issn><eissn>2084-9893</eissn><abstract>Actinic keratosis (AK) is a disease characterized by hyperkeratotic lesions on skin damaged by ultraviolet. radiation. These lesions may progress to squamous cell or basal cell carcinoma. Currently pharmacotherapy and different surgical procedures are used in AK therapy. The most common treatment options are 5-fluorouracil, imiquimod, diclofenac, ingenol mebutate, and first and third generation retinoids (retinol, adapalene, tazarotene). Furthermore, research is being carried out in order to test new medications including nicotinamide, resiquimod, piroxicam, potassium dobesilate and oleogel based on a triterpene extract (betulin, betulinic acid). Recently, the preventive effect of acetylsalicylic acid and celecoxib has also been investigated.</abstract><cop>Poznan</cop><pub>Termedia Publishing House</pub><doi>10.5114/dr.2016.61784</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0033-2526
ispartof Przegląd dermatologiczny, 2016-01, Vol.4 (4), p.330-336
issn 0033-2526
2084-9893
language eng ; pol
recordid cdi_doaj_primary_oai_doaj_org_article_a146cc97b02c41d7a805dca8277a1636
source Publicly Available Content (ProQuest)
subjects actinic keratosis
clinical studies
pharmacotherapy
title Pharmacological treatment of actinic keratosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A37%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20treatment%20of%20actinic%20keratosis&rft.jtitle=Przegla%CC%A8d%20dermatologiczny&rft.au=Zwierzy%C5%84ska,%20Ewa&rft.date=2016-01-01&rft.volume=4&rft.issue=4&rft.spage=330&rft.epage=336&rft.pages=330-336&rft.issn=0033-2526&rft.eissn=2084-9893&rft_id=info:doi/10.5114/dr.2016.61784&rft_dat=%3Cproquest_doaj_%3E4179545001%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-3de4b679cd71ce5ffd2e82e85ed4bb74956a605ad702f0fc7f54fb3459f1d9653%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1818675573&rft_id=info:pmid/&rfr_iscdi=true